DBV Technologies (DBVT) EBT (2020 - 2026)
DBV Technologies (DBVT) posted EBT of -$50.2 million for Q2 2026, down 5.91% sequentially from -$47.4 million in Q1 2026, and down 20.1% YoY from -$62.8 million in Q2 2025.
Analysis
DBV Technologies (DBVT) EBT (2020 - 2026) Analysis & Trends
DBV Technologies has reported EBT for 7 years, with the latest figure at -$50.2 million in Q2 2026.
- Quarterly EBT fell 20.1% year-over-year to -$50.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$175.2 million (down 43.21% YoY) and the FY2025 annual result came in at -$146.5 million, down 28.62% from the prior year.
- EBT retreated to -$50.2 million in Q2 2026 per DBVT's latest filing, from -$47.4 million in the prior quarter.
- Over five years, EBT peaked at -$11.2 million in Q4 2023 and troughed at -$50.2 million in Q2 2026.
- A 5-year average of -$29.3 million and a median of -$27.2 million in 2024 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2023: EBT slumped 187.63% in 2022, then jumped 71.49% in 2023.
- Over 5 years, EBT stood at -$39.3 million in 2022, then surged by 71.49% to -$11.2 million in 2023, then slumped by 105.58% to -$23.0 million in 2024, then plunged by 93.22% to -$44.5 million in 2025, then retreated by 12.92% to -$50.2 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$50.2 million, -$47.4 million, and -$44.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 542.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -767.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 312.46 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 177.81 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -11.37 Mn |
| 10 | DBV Technologies | 5.88 Bn | 5.70 Bn | - | -50.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -50.20 Mn |
| Mar 31, 2026 | -47.40 Mn |
| Dec 31, 2025 | -44.46 Mn |
| Sep 30, 2025 | -33.16 Mn |
| Jun 30, 2025 | -41.80 Mn |
| Mar 31, 2025 | -27.10 Mn |
| Dec 31, 2024 | -23.01 Mn |
| Sep 30, 2024 | -30.44 Mn |
| Jun 30, 2024 | -33.12 Mn |
| Mar 31, 2024 | -27.30 Mn |
| Dec 31, 2023 | -11.19 Mn |
| Sep 30, 2023 | -16.74 Mn |
| Jun 30, 2023 | -24.23 Mn |
| Mar 31, 2023 | -20.56 Mn |
| Dec 31, 2022 | -39.26 Mn |
| Sep 30, 2022 | -17.29 Mn |
| Jun 30, 2022 | -23.04 Mn |
| Mar 31, 2022 | -16.62 Mn |
| Dec 31, 2021 | -13.65 Mn |
| Sep 30, 2021 | -24.03 Mn |